Ifebemtinib
As of the edition of 20 October 2026, Ifebemtinib is a small molecule: in active development; acts on PTK2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2027
- Kind
- Small molecule
- Registered trials
- 16, 1 stopped early
- Disease areas
- Cancer; Lungs and airways; Digestive system; Hormones; Nervous system; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PTK2 | Focal adhesion kinase 1 | Q05397 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 6 | 4 | 2 | 0 |
| Phase 2 | 9 | 1 | 7 | 1 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 16 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Boehringer Ingelheim | Lead sponsor of trials | 2011 to now |
| InxMed | Lead sponsor of trials | 2020 to now |
| InventisBio | Lead sponsor of trials | 2022 to now |
| Jemincare | Lead sponsor of trials | 2025 to now |